

## Vowst

### Member Information

1. Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Trillium ID #: \_\_\_\_\_ 4. Date of Birth: \_\_\_\_\_ 5. Gender: \_\_\_\_\_

### Prescriber Information

1. Prescriber Name: \_\_\_\_\_ 2. NPI #: \_\_\_\_\_  
3. Requestor Name (Nurse/Office Staff): \_\_\_\_\_  
4. Mailing Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_  
5. Phone #: \_\_\_\_\_ Ext. \_\_\_\_\_ Fax #: \_\_\_\_\_

### Drug Information

1. Drug Name: \_\_\_\_\_ 2. Strength: \_\_\_\_\_ 3. Quantity per 30 Days: \_\_\_\_\_  
4. Length of Therapy (in Days): ☐ up to 30 Days ☐ 60 Days ☐ 90 Days ☐ 120 Days ☐ 180 Days ☐ 365 Days ☐ Other \_\_\_\_\_

### Clinical Information

1. Is the member  $\geq 18$  years of age? ☐ Yes ☐ No  
2. Does the member have a confirmed diagnosis of recurrent *Clostridioides difficile* infection (CDI) with a total of  $\geq 3$  episodes of CDI within 12 months? ☐ Yes ☐ No  
3. Will antibiotic treatment for recurrent CDI be completed 2 to 4 days prior to initiation of Vowst therapy?  
☐ Yes ☐ No  
4. Will the member take 10 oz of magnesium citrate (or 250 mL polyethylene glycol electrolyte solution for patients with impaired kidney function) the evening prior to initiation of Vowst therapy? ☐ Yes ☐ No  
5. Is the member's absolute neutrophil count (ANC)  $> 500$  cells/mm<sup>3</sup>? ☐ Yes ☐ No  
6. Does the member have toxic megacolon? ☐ Yes ☐ No  
7. Does the member have small bowel ileus? ☐ Yes ☐ No

Signature of Prescriber: \_\_\_\_\_ Date: \_\_\_\_\_

**(Prescriber Signature Mandatory)**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.